CEPI Developments
Following up from the last newsletter, the Coalition for Epidemic Preparedness Innovations (CEPI), established and supported by several GloPID-R members, is continuing its outreach efforts by presenting to various stakeholder groups.
Recently, CEPI presented at the WHO member state briefing in Geneva on November 17, 2016, where over 50 member states were present.
On November 18, 2016, CEPI hosted the first meeting of its Joint Coordination Group at the Who Headquarters in Geneva. Ex-FDA Commissioner Margaret Hamburg chaired the meeting to discuss key issues:
- regulatory science and stockpiling of candidate vaccines,
- shared costs/benefits with product developers from private sector,
- pull-mechanisms working with entities such as GAVI to further incentivize R&D,
- importance of vaccine platforms that can be used/leveraged for several diseases, and
- CEPI’s central role in advocacy and resource mobilisation.
Line Matthiessen, Chair of GloPID-R and Serge Desnoyers, from CIHR, represented GloPID-R at the meeting and participated in a panel discussion. Other meeting participants included representatives from governments, industry, other private sector organizations, and NGOs, including US BARDA, UK DH, EC DG Research and Innovation, WHO, World Bank, GAVI, and the Global Health Investment Fund (GHIF).
CEPI is a new coalition of stakeholders from international organizations, governments, industry, public and philanthropic R&D funders, academia, NGOs and civil society groups who agreed to explore new ways of working to drive vaccine innovation to address public health threats, in alignment with the WHO Blueprint for R&D.
CEPI and the founding partners are currently actively seeking partnerships with governments, potential funders, industry partners, regulators, and civil society organisations with an interest in building a proactive and accelerated approach to vaccine development and delivery.
CEPI will be officially launched at Davos in January 2017.
